Corcept Therapeutics Statistics

Total Valuation

Corcept Therapeutics has a market cap or net worth of GBP 5.02 billion. The enterprise value is 4.58 billion.

Market Cap	5.02B
Enterprise Value	4.58B

Important Dates

The next estimated earnings date is Friday, February 14, 2025.

Earnings Date	Feb 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-1.56%
Shares Change (QoQ)	+2.23%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	86.07M

Valuation Ratios

The trailing PE ratio is 47.91.

PE Ratio	47.91
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	10.54
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 38.45, with an EV/FCF ratio of 43.07.

EV / Earnings	43.72
EV / Sales	8.98
EV / EBITDA	38.45
EV / EBIT	39.37
EV / FCF	43.07

Financial Position

The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.01.

Current Ratio	3.70
Quick Ratio	3.51
Debt / Equity	0.01
Debt / EBITDA	0.05
Debt / FCF	0.05
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 25.77% and return on invested capital (ROIC) is 16.18%.

Return on Equity (ROE)	25.77%
Return on Assets (ROA)	13.00%
Return on Capital (ROIC)	16.18%
Revenue Per Employee	1.33M
Profits Per Employee	297,777
Employee Count	352
Asset Turnover	0.91
Inventory Turnover	1.26

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +130.53% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+130.53%
50-Day Moving Average	55.20
200-Day Moving Average	39.69
Relative Strength Index (RSI)	64.86
Average Volume (20 Days)	628

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	17.32

Income Statement

In the last 12 months, Corcept Therapeutics had revenue of GBP 468.96 million and earned 104.82 million in profits. Earnings per share was 0.94.

Revenue	468.96M
Gross Profit	461.65M
Operating Income	106.96M
Pretax Income	124.11M
Net Income	104.82M
EBITDA	107.50M
EBIT	106.96M
Earnings Per Share (EPS)	0.94

Full Income Statement

Balance Sheet

The company has 283.77 million in cash and 5.07 million in debt, giving a net cash position of 403.53 million.

Cash & Cash Equivalents	283.77M
Total Debt	5.07M
Net Cash	403.53M
Net Cash Per Share	n/a
Equity (Book Value)	476.63M
Book Value Per Share	4.55
Working Capital	254.24M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 107.93 million and capital expenditures -1.53 million, giving a free cash flow of 106.40 million.

Operating Cash Flow	107.93M
Capital Expenditures	-1.53M
Free Cash Flow	106.40M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 98.44%, with operating and profit margins of 22.81% and 22.56%.

Gross Margin	98.44%
Operating Margin	22.81%
Pretax Margin	26.46%
Profit Margin	22.56%
EBITDA Margin	22.92%
EBIT Margin	22.81%
FCF Margin	22.69%

Dividends & Yields

Corcept Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.56%
Shareholder Yield	1.56%
Earnings Yield	2.09%
FCF Yield	2.12%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Corcept Therapeutics has an Altman Z-Score of 15.07.

Altman Z-Score	15.07
Piotroski F-Score	n/a